Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effectiveness of Intravitreal Injection of Aflibercept 8 mg in Resistant Diabetic Macular Edema and Retinal Vein Occlusion Patients

NCT06879301 is registered in ClinicalTrials.gov with Tanta University as lead sponsor.

NCT NCT06879301
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06879301 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effectiveness of Intravitreal Injection of Aflibercept 8 mg in Resistant Diabetic Macular Edema and Retinal Vein Occlusion Patients
Lead sponsor
Tanta University
Phase
Phase 1
Overall status
Completed
Start date
March 19, 2025
Completion date
July 19, 2026
Enrollment
60 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema (dme), myopic choroidal neovascularisation, retinal vein occlusion (rvo)